Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | POLA1 | P09884 | 1/20 | 0.74 |
| ▸ | POLG | P54098 | 1/20 | 0.74 |
| ▸ | HPRT1 | P00492 | 12/20 | 0.66 |
| ▸ | PNP | P00491 | 6/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734888 | 0.91 | POLB (0.73) | POLBPOLA1POLGHPRT1PNP | |
| Gs-438 SCHEMBL64567 | 0.91 | POLB (0.80) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL9055784 | 0.89 | POLB (0.81) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL24721833 | 0.89 | POLB (0.74) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL24721866 | 0.88 | POLB (0.73) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL8717524 | 0.87 | POLB (0.81) | POLBPOLA1POLGHPRT1PNP | |
| Gs-438 SCHEMBL3497651 | 0.87 | POLB (0.84) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL9053987 | 0.86 | POLB (0.76) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL9054336 | 0.86 | POLB (0.76) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL17617679 | 0.86 | POLB (0.76) | POLBPOLA1POLGHPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-01-18 | — | — | US | disclosed |
| US-9801884-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170037068-A1 | NUCLEOTIDE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-09 | — | — | US | disclosed |
| US-9493493-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2016-03-24 | — | — | US | disclosed |
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011011710-A1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | POLB 204/4885POLA1 438/4885POLG 423/4885 |
| US-20180015095-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885POLA1 350/4885POLG 524/4885 |
| US-20160083407-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20170037068-A1 | NUCLEOTIDE ANALOGS | NUDT1, DUT, DPYD | POLB 29/4885POLA1 97/4885POLG 120/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885POLA1 350/4885POLG 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.